Citi upgraded Blueprint Medicines (BPMC) to Neutral from Sell with a price target of $129, up from $83, following the announcement that Blueprint will be acquired by Sanofi (SNY) in a cash transaction of $129 per share plus contingent value rights considerations for pipeline asset BLU-80. At this time, Citi does not expect regulatory hurdles or competitive bids to impact the transaction.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- Blueprint Medicines downgraded to Neutral from Buy at Guggenheim
- Reddit initiated, Pinterest upgraded: Wall Street’s top analyst calls
- Blueprint Medicines downgraded to Equal Weight from Overweight at Stephens
- Blueprint downgraded to Market Perform from Outperform at Citizens JMP
- Blueprint Medicines downgraded to Hold from Buy at TD Cowen